ISPOR 21st ANNUAL INTERNATIONAL MEETING

May 21-25, 2016
Washington Hilton | Washington, DC, USA

PROGRAM & SCHEDULE OF EVENTS
**Saturday, May 21**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00AM-5:00PM</td>
<td><strong>SHORT COURSE FULL DAY</strong> Separate Registration Required (Please see ISPOR Registration)</td>
<td><strong>INTRODUCTION TO PHARMACOECONOMICS</strong> Intl Ballroom West (Entrance-Terrace Level)  &lt;br&gt; <strong>BAYESIAN ANALYSIS - OVERVIEW AND APPLICATIONS</strong> Georgetown West (Concourse Level)</td>
</tr>
<tr>
<td>8:00AM-12:00PM</td>
<td><strong>SHORT COURSE MORNING SESSION</strong> Separate Registration Required (Please see ISPOR Registration)</td>
<td><strong>NEW! INFORMATICS AND INTEROPERABILITY: SPEAKING THE SAME LANGUAGE</strong> Georgetown East (Concourse Level)  &lt;br&gt; <strong>INTRODUCTION TO THE DESIGN &amp; ANALYSIS OF OBSERVATIONAL STUDIES OF TREATMENT EFFECTS USING RETROSPECTIVE DATA SOURCES</strong> Jefferson West (Concourse Level)  &lt;br&gt; <strong>INTRODUCTION TO MODELING METHODS</strong> Jefferson East (Concourse Level)  &lt;br&gt; <strong>INTRODUCTION TO PATIENT-REPORTED OUTCOMES</strong> Monroe (Concourse Level)  &lt;br&gt; <strong>INTRODUCTION TO CONJOINT ANALYSIS</strong> Cabinet (Concourse Level)  &lt;br&gt; <strong>ELEMENTS OF PHARMACEUTICAL/BIOTECH PRICING I - INTRODUCTION</strong> Lincoln West (Concourse Level)  &lt;br&gt; <strong>COST-EFFECTIVENESS ANALYSIS ALONGSIDE CLINICAL TRIALS</strong> Lincoln East (Concourse Level)</td>
</tr>
<tr>
<td>1:00PM-5:00PM</td>
<td><strong>SHORT COURSE AFTERNOON SESSION</strong> Separate Registration Required (Please see ISPOR Registration)</td>
<td><strong>META-ANALYSIS AND SYSTEMATIC REVIEWS IN COMPARATIVE EFFECTIVENESS RESEARCH</strong> Lincoln East (Concourse Level)  &lt;br&gt; <strong>UTILITY MEASURES</strong> Georgetown East (Concourse Level)  &lt;br&gt; <strong>MODELING: DESIGN AND STRUCTURE OF A MODEL</strong> Jefferson East (Concourse Level)  &lt;br&gt; <strong>CASE STUDIES IN PHARMACEUTICAL/BIOTECH PRICING II - ADVANCED</strong> Lincoln West (Concourse Level)  &lt;br&gt; <strong>USE OF PROPENSITY SCORES IN OBSERVATIONAL STUDIES OF TREATMENT EFFECTS</strong> Jefferson West (Concourse Level)  &lt;br&gt; <strong>ADVANCED PATIENT-REPORTED OUTCOMES</strong> Monroe (Concourse Level)  &lt;br&gt; <strong>VALUE OF INFORMATION AND PROBABILISTIC ANALYSES</strong> Cabinet (Concourse Level)</td>
</tr>
</tbody>
</table>

---

**Sunday, May 22**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00AM-12:00PM</td>
<td><strong>SHORT COURSE MORNING SESSION</strong> Separate Registration Required (Please see ISPOR Registration)</td>
<td><strong>DISCRETE EVENT SIMULATION FOR ECONOMIC ANALYSES - CONCEPTS</strong> Georgetown East (Concourse Level)  &lt;br&gt; <strong>STATISTICAL METHODS IN ECONOMIC EVALUATIONS</strong> Intl Ballroom East (Concourse Level)  &lt;br&gt; <strong>RISK-SHARING/PERFORMANCE-BASED ARRANGEMENTS FOR DRUGS AND OTHER MEDICAL PRODUCTS</strong> Intl Ballroom West (Entrance-Terrace Level)  &lt;br&gt; <strong>APPLICATIONS IN USING LARGE DATABASES</strong> Monroe (Concourse Level)  &lt;br&gt; <strong>PATIENT-REPORTED OUTCOMES - ITEM RESPONSE THEORY</strong> Lincoln (Concourse Level)  &lt;br&gt; <strong>USE OF INSTRUMENTAL VARIABLES IN OBSERVATIONAL STUDIES OF TREATMENT EFFECTS</strong> Georgetown West (Concourse Level)  &lt;br&gt; <strong>BUDGET IMPACT ANALYSIS I: A 6-STEP APPROACH</strong> Jefferson (Concourse Level)</td>
</tr>
<tr>
<td>1:00PM-5:00PM</td>
<td><strong>SHORT COURSE AFTERNOON SESSION</strong> Separate Registration Required (Please see ISPOR Registration)</td>
<td><strong>NEW! ADVANCED TOPICS IN DECISION ANALYTIC MODELING</strong> Georgetown West (Concourse Level)  &lt;br&gt; <strong>INTRODUCTION TO BIG DATA ANALYSIS: GRAPH ANALYTICS</strong> Monroe (Concourse Level)  &lt;br&gt; <strong>BUDGET IMPACT ANALYSIS II: APPLICATIONS &amp; DESIGN ISSUES</strong> Jefferson (Concourse Level)  &lt;br&gt; <strong>DISCRETE EVENT SIMULATION FOR ECONOMIC ANALYSES - APPLICATIONS</strong> Georgetown East (Concourse Level)  &lt;br&gt; <strong>NETWORK META-ANALYSIS</strong> Lincoln (Concourse Level)  &lt;br&gt; <strong>ADVANCED DECISION MODELING FOR HEALTH ECONOMIC EVALUATIONS</strong> Intl Ballroom East (Concourse Level)  &lt;br&gt; <strong>USING MULTI-CRITERIA DECISION ANALYSIS IN HEALTH CARE DECISION MAKING: APPROACHES &amp; APPLICATIONS</strong> Intl Ballroom West (Entrance-Terrace Level)</td>
</tr>
</tbody>
</table>
### Monday, May 23

#### 7:15AM-8:15AM  
**EDUCATIONAL SYMPOSIUM  
Jefferson (Concourse Level)**

**CHALLENGES AND OPPORTUNITIES IN VALUE-BASED CANCER CARE: ASSESSING THE MULTI-DIMENSIONAL INFLUENCE OF VALUE ASSESSMENT AND STANDARDIZED VALUE ALGORITHMS ON TREATMENT CHOICE FROM CLINICAL, POLICY, AND HEOR VIEWPOINTS**

Sponsored by Cardinal Health

#### 7:30AM-8:30AM  
**ISPOR STATED PREFERENCE METHODS SPECIAL INTEREST GROUP OPEN MEETING  
Embassy (Terrace Level)**

If you are interested in benefit risk assessment, discrete choice experiments, and other preference-based research, please join members of the Special Interest Group at this meeting. Current and new projects will be discussed.

#### 8:30AM-2:00PM  
**RESEARCH POSTER PRESENTATIONS - SESSION I  
Columbia (Terrace Level)**

#### 8:30AM-10:30AM  
**WELCOME & FIRST PLENARY SESSION  
Intl Ballroom (Entrance-Terrace Level)**

**WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTOR**

Nancy S. Berg, BSc, CEO/Executive Director, ISPOR, Lawrenceville, NJ, USA

**PRESIDENTIAL ADDRESS**

Daniel Malone, PhD, RPh, 2015-2016 ISPOR President, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
MEETING PROGRAM OVERVIEW

Bradley C. Martin, PharmD, RPh, PhD, Program Committee Co-Chair and Professor & Head, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

Eleanor M. Perfetto, PhD, MS, Program Committee Co-Chair, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC, and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA

2016 ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award

Presented by: Mark J. Sculpher, MSc, PhD, Chair, ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award Committee

AWARDEE: Pennifer A. Erickson, PhD, Co-founder, OLGA, State College, PA, USA

FIRST PLENARY SESSION: ACCELERATING CURES: ADDRESSING UNMET PATIENT NEED OR PUTTING PATIENTS AT RISK?

We have witnessed remarkable policy efforts geared toward shortening the timeline to bring medical products to patients in need. Legislative proposals aimed at accelerating the development of biopharmaceutical and other medical products have had bipartisan backing, as well as support from various stakeholder groups. However, these efforts have also drawn fire from opponents concerned they may circumvent patient safety. In this session, we will hear alternative views on accelerated development efforts, as well as the patient view on this issue. Speakers will summarize where we are globally on accelerating cures, highlight outstanding issues and questions being debated, and discuss where we are headed in terms of future proposals.

Moderator: Eleanor M. Perfetto, PhD, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA

Speakers: Jerry Avorn, MD, Professor of Medicine, Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
Scott Gottlieb, MD, Resident Fellow, American Enterprise Institute, Washington, DC, USA
Patricia Furlong, Founding President & Chief Executive Officer, Parent Project Muscular Dystrophy (PPMD), Middletown, OH, USA

10:30AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I

Columbia & Intl Terrace (Terrace Level) and Concourse Lobby

Coffee Break Sponsored by Kantar Health

11:00AM-12:00PM ISSUE PANELS - SESSION I

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP1: PAYERS’ USE OF INDEPENDENT REPORTS IN DECISION MAKING – WILL THERE BE AN ICER EFFECT? Intl Ballroom West (Entrance-Terrace Level)

Moderator: Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Panelists: Allen Lising, PhD, Managing Director, Dymaxium Inc, Toronto, ON, Canada; Michael Barry, MD, PhD, Clinical Director, National Centre for Pharmacoconomics, Dublin, Ireland; Federico Augustovski, MD, Director, Health Technology Assessment and Health Economic Department, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

IP2: ARE WE READY FOR A CURE? KEY VALUE DEMONSTRATION AND POLICY CONSIDERATIONS FOR THE NEW WAVE OF POTENTIALLY CURATIVE THERAPIES Intl Ballroom East (Concourse Level)

Moderator: Eric Faulkner, MPH, Vice President, Precision and Transformative Technology Solutions, Evidera, Durham, NC, USA
Panelists: Simu K. Thomas, PhD, Global Head, Market Access and HEOR, Cell and Gene Therapies Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Tamara Syrek Jensen, MD, Acting Director, Coverage and Analysis Group, Center for Medicare and Medicaid Services, Baltimore, MD, USA; Gregory W. Daniel, PhD, MPH, RPh, Deputy Director, Duke-Robert J. Margolis, MD Center for Health Policy, Duke University, Washington, DC, USA

IP3: WHAT’S NEXT FOR VALUE FRAMEWORKS FOR PRESCRIPTION DRUGS? Intl Ballroom Center (Entrance-Terrace Level)

Moderator: Peter J. Neumann, ScD, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Panelists: Lowell E. Schnipper, MD, Theodore and Evelyn Berenson Professor of Medicine, Harvard Medical School, Clinical Director, Cancer Center, and Chief, Hematology/Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA; Dan Ollendorf, PhD, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA; Joshua Ofman, MD, MSHS, Senior Vice President, Global Value and Access and Policy, Amgen, Thousand Oaks, CA, USA

ECONOMIC OUTCOMES RESEARCH ISSUES

IP4: ASSESSING THE VALUE OF MEDICAL DEVICES — CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE?
Jefferson (Concourse Level)
Moderator: Bruce Gingles, BA, Vice President - Global Technology Assessment and Healthcare Policy, Cook Medical, Bloomington, IN, USA
Panelists: Nneka C. Onwudiwe, PhD, PharmD, MBA, PRO/PE Regulatory Reviewer, Office of Prescription Drug Promotion, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA; Andrew M. Baker, MPA, MBA, Director, Health Policy & Reimbursement, Stryker, Mahwah, NJ, USA; Suzanne Belinson, PhD, MPH, Executive Director, Center for Clinical Effectiveness, Blue Cross Blue Shield Association, Chicago, IL, USA

USE OF REAL WORLD DATA ISSUES

IP5: USE OF REAL-WORLD EVIDENCE IN PAYER DECISION MAKING: FACT OR FICTION? Lincoln (Concourse Level)
Moderator: Daniel Malone, RPh, PhD, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
Panelists: Craig Mattson, MS, MBA, RPh, Senior Director, Formulary Development, Prime Therapeutics, Eagan, MN, USA; John W. McKnight, PharmD, BCPS, Director, HPS Clinical Strategies, Humana, Louisville, KY, USA; Steven G. Avey, RPh, MS, FAMCP, Vice President, Specialty Pharmacy, MedImpact, San Diego, CA, USA

12:00PM-2:15PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATION VIEWING - SESSION I Columbia & Intl Terrace (Terrace Level) and Concourse Lobby
Lunch Sponsored by BaseCase Management GmbH

12:30PM-1:30PM EDUCATIONAL SYMPOSIUM Intl Ballroom East (Concourse Level)
HOW REAL-WORLD EVIDENCE CAN ENABLE PHARMA TO PARTNER IN HEALTH CARE DELIVERY
Sponsored by IMS Health

12:30PM-1:45PM ISPOR STUDENT RESEARCH SHOWCASE Intl Ballroom West (Entrance-Terrace Level)
OUTCOMES RESEARCH HAVING A HIGH IMPACT ON VALUE, AFFORDABILITY, AND PATIENT CENTEREDNESS: CAN WE HAVE IT ALL?
This showcase session will feature four outcomes research studies, conducted by ISPOR student members and presented during the ISPOR 21st Annual International Meeting. A brief summary of the research study and conclusions will be presented by each student author followed by a discussion of the impact of Value, Affordability, and Patient Centeredness: Can We Have it All?
Moderators: Dennis Raisch, PhD, Professor, University of New Mexico, College of Pharmacy, Albuquerque, NM, USA; Laura Pizzi, PhD, Professor, Jefferson College of Pharmacy, Philadelphia, PA, USA; Zeba M. Khan, PhD, RPh, Vice President, Celgene Corporation, Summit, NJ, USA
Speakers: Jeffrey Thompson, PhD Candidate, University of Cincinnati, Cincinnati, OH, USA; Xinke Zhang, University of Southern California, Los Angeles, CA, USA; Mriganka Pal, St. Peter’s Institute of Pharmaceutical Sciences, Telangana, India; Robert B. Milenkovski, University of Toronto, Mississauga, ON, Canada

12:30PM-1:45PM ISPOR DIGEST OF INTERNATIONAL DATABASES SPECIAL INTEREST GROUP OPEN MEETING Georgetown (Concourse Level)
All ISPOR members interested in learning about or updating the ISPOR Digest of Databases are welcome to attend. This meeting will provide background information and objectives in updating the ISPOR Digest of Databases, an electronic index (digest) of 400 databases from 45 countries consisting of key attributes of health care databases. The goal is to encourage and enlist the assistance of the audience to understand the importance of providing access to up-to-date research organization information.

1:00PM-2:00PM POSTER AUTHOR DISCUSSION HOUR - SESSION I Columbia (Terrace Level)

2:15PM-3:15PM RESEARCH PODIUM PRESENTATIONS - SESSION I
(Page numbers refer to Podium Abstracts in Value in Health 19(3))

BUDGET IMPACT STUDIES Intl Ballroom West (Entrance-Terrace Level)
Moderator: Laura Pizzi, MPH, Professor, Thomas Jefferson University, Philadelphia, PA, USA

pgA1 BI1 RETURN ON INVESTMENT OF A DIGITAL LIFESTYLE MANAGEMENT PROGRAM IN A MEDICARE POPULATION
ESTIMATING THE COSTS OF SUPPORTING SAFETY-NET TRANSFORMATION INTO PATIENT-CENTERED MEDICAL HOMES IN POST-KATRINA NEW ORLEANS
Shao H¹, Shi L¹, Diana M¹, Brown L¹, Mason K², Cocran D², Carruth A², Carruth A², Schmidt L³, ¹Tulane University, New Orleans, LA, USA, ²Louisiana Public Health Institute, New Orleans, LA, USA, ³University of California at San Francisco, San Francisco, CA, USA

ASSESSING PRESCRIPTION DRUG VALUE IN THE UNITED STATES: A HYPOTHETICAL EXAMPLE COMPARING ASCO AND ICER FRAMEWORK OUTCOMES
Bozkaya D, Migliaccio-Walle K, O’Day K, Xcenda, Palm Harbor, FL, USA

WITHDRAWN

COMPARATIVE EFFECTIVENESS OF CORONARY ARTERY BYPASS GRAFTING VERSUS PERCUTANEOUS CORONARY INTERVENTION AMONG ELDERLY MEDICARE BENEFICIARIES IN TERMS OF COST AND RESOURCE USE
Shah R, Yang Y, Bentley JP, Banahan III B, University of Mississippi, University, MS, USA

BAYESIAN NETWORK META-ANALYSIS TO ASSESS COMPARATIVE EFFECTIVENESS OF BETA-BLOCKERS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
Aggarwal S¹, Kumar S², Topaloglu H¹, ¹NOVEL Health Strategies, Chevy Chase, MD, USA, ²Institute for Global Policy Research, Washington, DC, USA

COMPARATIVE EFFECTIVENESS OF PANITUMUMAB VERSUS CETUXIMAB IN PATIENTS WITH CHEMO-REFRACTORY WILD-TYPE KRAS METASTATIC COLORECTAL CANCER
Xu Y, Hay JW, Barzi A, University of Southern California, Los Angeles, CA, USA

SELECT RESOURCE UTILIZATION DURING ADVANCED RENAL CELL CARCINOMA TREATMENT: COMPARISON OF TARGETED DRUG CLASSES
Feinberg BA¹, Garofalo DF¹, Drenning J², ¹Cardinal Health, Dublin, OH, USA, ²Cardinal Health, Dallas, TX, USA

COMPARATIVE COST AND RESOURCE UTILIZATION IN HOSPITALIZED PATIENTS TREATED WITH UNFRACTIONATED HEPARIN MONITORED BY ANTI-XA OR APTT
Craver CW¹, Belk K², Verma K³, ¹MedAssets, Inc., Huntersville, NC, USA, ²MedAssets, Mooresville, NC, USA, ³Instrumentation Laboratory, Bedford, MA, USA

EFFECTIVENESS AND SAFETY OF REDUCED DOSE NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITHOUT SEVERE RENAL IMPAIRMENT
Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA, Mayo Clinic, Rochester, MN, USA

HOW LIPID-LOWERING THERAPY IMPACTS LIPID ABNORMALITIES AMONG ACS PATIENTS IN HONG KONG HOSPITAL—A RETROSPECTIVE STUDY
L¹, Cheng TC¹, Yan BP¹, ¹The Chinese University of Hong Kong, Shatin, Hong Kong, ²University of Southern California, Los Angeles, CA, USA

COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES
Gandra SR¹, Villa G¹, Fonarow G², Lothgren M¹, Lindgren P¹, Somaratne R¹, van Hout B¹, ¹Amgen, Inc., Thousand Oaks, CA, USA, ²Amgen (Europe) GmbH, Zug, Switzerland, ³Geffen-UCLA School of Medicine, Los Angeles, CA, USA, ⁴The Swedish Institute for Health Economics, Karolinska Institutet, Stockholm, Sweden, ⁵University of Sheffield, Sheffield, UK

UTILIZATION PATTERNS OF LIPID-LOWERING MEDICATIONS IN HIGH RISK DIABETIC PATIENTS
Vadharaya A, Aparasu R, University of Houston, Houston, TX, USA

MEDICARE PART D COST SHARING AND SPECIALTY DRUG INITIATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS
Doshi J¹, Li P¹, Huo H¹, Pettit AR¹, Kumar R¹, Huntington SP², Weiss BM¹, ¹University of Pennsylvania, Philadelphia, PA, USA, ²Yale University, New Haven, CT, USA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, USA
PROGRAM & SCHEDULE OF EVENTS: MONDAY, MAY 23

pgA3  ME3  POTENTIALLY INAPPROPRIATE ANTIDEPRESSANT USE AMONG OLDER ADULTS IN OFFICE-BASED SETTINGS IN THE UNITED STATES: TRENDS FROM 2002 TO 2012
2:45PM-3:00PM
Rhee TG1, Schommer JC1, Capistrant BD2, Hadsall RS1, Uden DL1, 1University of Minnesota College of Pharmacy, Minneapolis, MN, USA, 2University of Minnesota School of Public Health, Minneapolis, MN, USA

pgA3  ME4  COMPARING HEALTH CARE UTILIZATION AMONG THREE TREATMENT REGIMENS PROVIDED TO COMMERCIAL-INSURED PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1
3:00PM-3:15PM
Kim S1, Parente A, Avalere Health - An Inovalon Company, Bowie, MD, USA

PRESCRIPTION PRICING STUDIES  Lincoln (Concourse Level)

Moderator: Benjamin F. Banahan III, PhD, Director, Center for Pharmaceutical Marketing and Pricing and Professor, Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS, USA

pgA4  PR1  MARKET ACCESS AND PRICING DISPARITIES OF ANTICANCER DRUGS MARKETED IN THE OECD COUNTRIES: WHICH REALITY?
2:15PM-2:30PM
Aissaoui A1, Bin Sawad A1, 1Paris Dauphine University, PSL, Paris, France, 2MCPHS University, Boston, MA, USA

pgA4  PR2  GENERIC INJECTABLE SHORTAGES AND TRENDS IN AVERAGE SALES PRICE IN THE UNITED STATES
2:30PM-2:45PM
Hur P1, Vegesna A1, Obi EN1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Rutgers University, Piscataway, NJ, USA, 3Jefferson College of Population Health, Philadelphia, PA, USA

pgA4  PR3  PRICES OF DRUGS FOR CHRONIC USE WITH ORPHAN DESIGNATION IN THE UNITED STATES (1983-2014)
2:45PM-3:00PM
Alhawwashi S1, Seoane-Vazquez E2, Eguale T3, Rodriguez-Monguio R3, 1Security Forces Hospital, Riyadh, Saudi Arabia, 2MCPHS University, Boston, MA, USA, 3Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA, 4University of Massachusetts, Amherst, MA, USA

pgA4  PR4  ANALYSIS OF INDICATION EXPANSIONS FOR ORPHAN-DESIGNATED, FDA-APPROVED DRUGS LAUNCHED IN THE UNITED STATES BETWEEN 2005 AND 2015
3:00PM-3:15PM
Li J1, Lai R1, Asabere A, Bastian A, GfK, San Francisco, CA, USA

SYSTEMIC DISORDERS STUDIES  Georgetown (Concourse Level)

Moderator: Andrew M. Peterson, PharmD, PhD, FCPP, John Wyeth Dean, Mayes College of Healthcare Business and Policy, University of the Sciences, Philadelphia, PA, USA

pgA4  SY1  NATURAL LANGUAGE PROCESSING-IDENTIFIED PROBLEM OPIOID USE AND ITS ASSOCIATED HEALTH CARE COSTS
2:15PM-2:30PM
Masters ET1, Mardekian J2, Ramaprakash A2, Saunders K2, Gross DE1, Palmer RE1, Cronkite D2, Von Korff M1, Carrell D1, 1Pfizer Inc., New York, NY, USA, 2Group Health Research Institute, Seattle, WA, USA

pgA4  SY2  DEALING WITH UNCERTAINTY AND ACCOUNTING FOR SOCIAL VALUE JUDGMENTS IN VALUE ASSESSMENTS FOR ORPHAN DRUGS: QUALITATIVE EVIDENCE FROM FOUR EUROPEAN COUNTRIES
2:30PM-2:45PM
Nicod E1, Berg Brigham K2, Durand-Zaleski I2, Kanavos P1, 1London School of Economics and Political Science, London, UK, 2URCEco Ile de France Hôpital de l’Hôtel Dieu, Paris, France

pgA4  SY3  EXPLORING ISSUES IN ANALYZING NATIONAL DATABASES USING LOGISTIC REGRESSION: APPLICATION OF MEDICAL EXPENDITURE PANEL SURVEY
2:45PM-3:00PM
Althemery AU1, Lai L1, Alfaiia A, Nova Southeastern University, Davie, FL, USA

pgA4  SY4  ECONOMIC EVALUATION OF AN AUTOMATED RETINAL IMAGE ANALYSIS IN AUSTRALIAN ABORIGINAL AND TORRES STRAIT ISLANDER POPULATIONS FOR DETECTION OF DIABETIC RETINOPATHY
3:00PM-3:15PM
Ballreich J1, Burnett A2, Frick K1, Ho A1, Arkapaw L2, Kleinert A2, 1Johns Hopkins University, Baltimore, MD, USA, 2Brien Holden Vision Institute and Vision Cooperative Research Centre, Sydney, Australia

3:15PM-3:45PM  BREAK & EXHIBITS VIEWING  Columbia & Intl Terrace (Terrace Level) and Concourse Lobby

3:45PM-4:45PM  RESEARCH PODIUM PRESENTATIONS - SESSION II
(Page numbers refer to Podium Abstracts in Value in Health 19(3))

COST-EFFECTIVENESS RESEARCH  Intl Ballroom Center (Entrance-Terrace Level)

Moderator: Patrick W. Sullivan, PhD, Professor, Regis University School of Pharmacy, Denver, CO, USA

pgA5  CE1  ECONOMIC ANALYSIS OF DRUG-COATED BALLOONS AND OTHER ENDOVASCULAR TREATMENTS FOR FEMOROPOPLITEAL ARTERY DISEASE IN THE UNITED KINGDOM
3:45PM-4:00PM
Piepszch JB1, Geisler BP1, Garner AM1, Zayed H2, Cleveland T1, Katsanos K1, 1Wing Tech Inc., Irvine, CA, USA, 2Guy’s and St. Thomas’ NHS Foundation Trust, London, UK, 3Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, 4Guy’s and St. Thomas’ Hospitals NHS Foundation Trust, London, UK
**PROGRAM & SCHEDULE OF EVENTS: MONDAY, MAY 23**

**CANCER OUTCOMES STUDIES**  
*Intl Ballroom East (Concourse Level)*  
**Moderator:** Timothy N. Showalter, MD, MPH, Associate Professor, Department of Radiation Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA  

**pgA5 CE2 COST EFFECTIVENESS OF ADDING CLOSTRIDIAL COLLAGENASE OINTMENT TO STANDARD OF CARE IN INDIVIDUALS WITH STAGE IV PRESSURE ULCERS**  
4:00PM-4:15PM  
Carter M1, Gilligan A2, Waycaster CR3, Schaum K4, 1Strategic Solutions Inc., Cody, WY, USA, 2Truvan Health Analytics, Ann Arbor, MI, USA, 3Smith & Nephew Inc., Fort Worth, TX, USA, 4Smith & Nephew Inc., Lake Worth, FL, USA  

**pgA5 CE3 ECONOMIC EVALUATION OF A MENTAL HEALTH ENGAGEMENT NETWORK**  
4:15PM-4:30PM  
Isaranuwatchai W1, Warner L2, Ethridge P3, Hoch JS4, Forchuk C5, 1St. Michael’s Hospital, Toronto, ON, Canada, 2University of Western Ontario, London, ON, Canada, 3University of California, Davis, Sacramento, CA, USA  

**pgA5 CE4 BARIATRIC SURGERY IN ADOLESCENTS: A COST-EFFECTIVENESS ANALYSIS**  
4:30PM-4:45PM  
Klebanoff MJ1, Chhatwal J2, Nudel JD3, Corey KE3, Kaplan LM3, Hur C4, 1Massachusetts General Hospital Institute for Technology Assessment, Boston, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3Harvard Medical School, Boston, MA, USA  

**ENDOCRINE DISORDERS STUDIES**  
*George-town (Concourse Level)*  
**Moderator:** R. Brett McQueen, PhD, Adjunct Assistant Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, CO, USA  

**pgA6 CN1 THE POTENTIAL CLINICAL, RESOURCE USE, AND FISCAL IMPACTS OF LUNG-RADS TO INFORM LUNG CANCER SCREENING IN MEDICARE**  
3:45PM-4:00PM  
Roth J1, Sullivan SD2, Ramsey S3, Goulart B4, 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA  

**pgA6 CN2 2015 UPDATE OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS ACROSS THE GLOBE: A FOCUS ON ONCOLOGY**  
4:00PM-4:15PM  
Clark RS1, Campbell CM, Meyer KL, Bramley TJ, Xcenda, LLC, Palm Harbor, FL, USA  

**pgA6 CN3 USE OF JOINPOINT REGRESSION TO DEFINE PHASES OF CARE IN PATIENTS WITH ADVANCED MELANOMA: AN EVALUATION FROM METASTATIC DIAGNOSIS UNTIL DEATH**  
4:15PM-4:30PM  
Nunna S1, Coutinho AP2, Eaddy M3, Landsman-Blumberg P4, 1University of Mississippi, University, MS, USA, 2Xcenda LLC, Palm Harbor, FL, USA, 3Xcenda, LLC, Palm Harbor, FL, USA  

**pgA6 CN4 A COST-EFFECTIVENESS ANALYSIS OF A TEST THAT PREDICTS RISK OF MALIGNANT PROGRESSION IN BARRETT’S ESOPHAGUS**  
4:30PM-4:45PM  
Hao J1, Snyder SR2, Pitcavage JM3, Critchley-Thorne R4, 1Geisinger Health System, Danville, PA, USA, 2Geisinger Center for Health Research, Danville, PA, USA, 3Cemostics Inc., Pittsburgh, PA, USA  

**pgA7 EN1 REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY INITIATED WITH ANTIHYPERGLYCEMIC MEDICATIONS IN THE UNITED STATES**  
3:45PM-4:00PM  
Cai J1, Burudpakdee C2, Divino V3, 1Janssen, Raritan, NJ, USA, 2IMS Health, Fairfax, VA, USA  

**pgA7 EN2 COMPARISON OF INSULIN AND NON-INSULIN TREATMENT MODIFICATION WITHIN 90 DAYS OF AN HBA1C GREATER THAN OR EQUAL TO 9% ON DIABETES PROGRESSION RATES IN A MEDICARE ADVANTAGE COHORT OVER 4 YEARS**  
4:00PM-4:15PM  
Abbass IM1, Collins JC2, Harvey RA3, Suesh B4, Uribe C5, Kimball E6, Bouchard J7, Renda AM8, DeLuzio T9, Allen E10, 1Comprehensive Health Insights, Inc., Louisville, KY, USA, 2Novo Nordisk, Inc., Plainsboro, NJ, USA, 3Humana, Louisville, KY, USA  

**pgA7 EN3 COST-EFFECTIVENESS OF DULAGLUITIDE, LIRAGLUITIDE, AND GLARGINE IN ADULT PATIENTS WITH DIABETES MELLITUS IN COLOMBIA**  
4:15PM-4:30PM  
Lasalvia P1, Baquero L2, Restrepo P3, Otálora M4, Castaña-Cardona C5, 1Pontificia Universidad Javeriana, Medical School, Bogota, Colombia, 2Neuroeconomix, Bogota, Colombia, 3Pontificia Universidad Javeriana, Bogota, Colombia  

**pgA7 EN4 ESTIMATING THE SOCIETAL COSTS ASSOCIATED WITH GLP-1RAS IN THE UNITED STATES FOR THE TREATMENT OF TYPE 2 DIABETES**  
4:30PM-4:45PM  
Wang BC1, Nguyen H2, Furnback W3, 1Elysia Group Ltd, Taipei, Taiwan, 2AstraZeneca, Fort Washington, PA, USA, 3Elysia Group, LLC, New York, NY, USA, 4AstraZeneca, Columbus, PA, USA, 5University of Washington, Seattle, WA, USA
HEALTH CARE EXPENDITURE STUDIES  Jefferson (Concourse Level)

**Moderator:** Carl V. Asche, MBA, MSc, PhD, Research Professor of Medicine & Director, Center for Outcomes Research, University of Illinois College of Medicine at Peoria, IL, USA

**pgA7 HC1**
**3:45PM-4:00PM**
**PATIENT-CENTERED MEDICAL HOME AND ANNUAL HEALTH CARE EXPENDITURES AMONG CHILDREN WITH SPECIAL HEALTH CARE NEEDS: NEW EVIDENCE FROM MEDICAL EXPENDITURE PANEL SURVEY**
Lin C', Romley JA', Carlin C', 'University of Southern California, Los Angeles, CA, USA, 'Medica Research Institute, Minneapolis, MN, USA

**pgA7 HC2**
**4:00PM-4:15PM**
**EARLY IMPACT OF MEDICAID EXPANSION ON PRESCRIPTION DRUG UTILIZATION AND SPENDING**
Mahendraratnam N', Dusetzina S', Farley J', 'UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA, 'University of North Carolina, Chapel Hill, NC, USA

**pgA7 HC3**
**4:15PM-4:30PM**
**MULTI-INDICATION PRICING: PROS, CONS, AND ITS APPLICABILITY TO THE UNITED KINGDOM**

**pgA7 HC4**
**4:30PM-4:45PM**
**A COMPARISON OF INDICATIONS AND HTA DECISIONS FOR HEPATITIS C**

MEDICATION ADHERENCE STUDIES  Intl Ballroom West (Entrance-Terrace Level)

**Moderator:** Khalid M. Kamal, PhD, Associate Professor, Division of Clinical, Social and Administrative Sciences, Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA

**pgA8 MA1**
**3:45PM-4:00PM**
**MEDICATION ADHERENCE AMONG HIV/AIDS PATIENTS RECEIVING 340B-PURCHASED ANTIRETROVIRAL MEDICATIONS**
Clark B', Hou JG', Huang ES', Conti R', Chou C', 'Walgreen Co. Member of Walgreens Boots Alliance, Deerfield, IL, USA, 'University of Chicago, Chicago, IL, USA

**pgA8 MA2**
**4:00PM-4:15PM**
**HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES**
Agarwal P', Bias T', Sambamoorthi U', 'West Virginia University, Morgantown, WV, USA, 'West Virginia University, School of Pharmacy, Morgantown, WV, USA

**pgA8 MA3**
**4:15PM-4:30PM**
**PREDICTORS OF INTENTIONAL AND UNINTENTIONAL NON-ADHERENCE AND ASSOCIATED HEALTH UTILITIES AMONG WOMEN RECEIVING ORAL TREATMENTS FOR BREAST CANCER**
Goren A', Gupta S', Lee LK', Wen K', Geynisman DM', 'Kantar Health, New York, NY, USA, 'Kantar Health, Princeton, NJ, USA, 'Kantar Health, Foster City, CA, USA, 'Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA

**pgA8 MA4**
**4:30PM-4:45PM**
**IMPACT OF MEDICATION ADHERENCE ON HOSPITALIZATION IN MEDICAID**
Roebuck MC', Dougherty JS', 'RxEconomics LLC, Hunt Valley, MD, USA, 'PhRMA, Washington, DC, USA

PATIENT PREFERENCE STUDIES  Lincoln (Concourse Level)

**Moderator:** A. Simon Pickard, PhD, Professor, Departments of Pharmacy Systems, Outcomes and Policy College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

**pgA9 PP1**
**3:45PM-4:00PM**
**DOES A WEB-BASED DECISION AID HELP PARENTS IN MAKING A DECISION TO VACCINATE THEIR CHILD AGAINST HPV: FINDINGS FROM ALBERTA**
Tiwanaw S', Johnston C', Webb JA', 'Alberta Health Services, Calgary, AB, Canada, 'University of Calgary, Calgary, AB, Canada

**pgA9 PP2**
**4:00PM-4:15PM**
**ASSOCIATION BETWEEN WORK TIME LOSS AND QUALITY OF LIFE IN PATIENTS WITH HERPES ZOSTER: A POOLED ANALYSIS OF THE MASTER STUDIES**
Acosta C', Rampakakis E', Tsai T', Cheong HJ', Dhitavat J', Ortiz-Covarrubias A', Stutz M', Cashat-Cruz M', Monsanto H', 'Johnson K', Sampalis JS', Kawai K', 'Merck & Co., Kenilworth, NJ, USA, 'JSS Medical Research Inc., St-Laurent, QC, Canada, 'National Taiwan University Hospital, Taipei City, Taiwan, 'Korea University Guro Hospital, Seoul, Korea, 'The Republic of; 'Mahidol University, Bangkok, Thailand, 'Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico, 'Merck Sharp & Dohme SRL de CV, Mexico City, Mexico, 'Merck Sharp & Dohme IA LLC, Carolina, PR, PR, 'Harvard Medical School, Boston, MA, USA

**pgA9 PP3**
**4:15PM-4:30PM**
**VALIDITY OF HEALTH PREFERENCES ELICITED FROM CHILDREN: COMPARING CHOICE BLINDNESS AND STATED PREFERENCES BETWEEN CHILDREN AND ADULTS**
Law EH', Pickard A', Kaczynski A', Pickard AS', 'University of Illinois at Chicago, Chicago, IL, USA, 'Second City Outcomes Research LLC, Oak Park, IL, USA, 'University of Applied Sciences Neubrandenburg, Neubrandenburg, Germany

**pgA9 PP4**
**4:30PM-4:45PM**
**QALY GAINS IN CANCER COMPARED WITH CHRONIC DISEASES**
Sandberg EA', Thorat T', Neumann PJ', Chambers J', 'Tufts Medical Center, Boston, MA, USA, 'Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
3:45PM-7:45PM RESEARCH POSTER PRESENTATIONS - SESSION II Columbia (Terrace Level)

5:00PM-6:00PM WORKSHOPS - SESSION I

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W1: PROMOTING THE SAFE USE OF MEDICATIONS AND ENHANCING UNDERSTANDING OF STAKEHOLDERS’ OPINIONS Intl Ballroom East (Concourse Level)
Discussion Leaders: Christine S. Lee, PharmD, PhD, Health Scientist, CDER/PASE, U.S. Food and Drug Administration, Silver Spring, MD, USA; Junyang Wang, MS, Health Scientist, CDER/PASE, U.S. Food and Drug Administration, Silver Spring, MD, USA; David Smith, RPH, PhD, Senior Researcher, Kaiser, Portland, OR, USA; Deb Pasko, PharmD, MHA, Director, Center on Medication Safety and Quality, ASHP, Bethesda, MD, USA

USE OF REAL WORLD DATA

W2: RISK-SHARING AGREEMENTS FOR MANUFACTURERS AND COMMERCIAL PAYERS IN THE UNITED STATES: HOW CAN THEORY HELP PRACTICE? DESIGN AND ALIGNING INCENTIVES ARE KEY Intl Ballroom Center (Entrance-Terrace Level)
Discussion Leaders: Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA; Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK; Rajiv Mallick, PhD, Senior Director, Health Economics and Outcomes Research, BTG International Inc., West Conshohocken, PA, USA; Pete Fullerton, PhD, RPh, Principal, Strategic Pharmacy Innovations, Seattle, WA, USA

W3: BIOSIMILARS: CURRENT DEVELOPMENTS AND REAL-WORLD EVIDENCE GENERATION Intl Ballroom West (Entrance-Terrace Level)
Discussion Leaders: Jaclyn L. Bosco, PhD, MPH, Director of Epidemiology, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA; Gregory W. Daniel, PhD, MPH, RPh, Deputy Director, Duke-Robert J. Margolis, MD Center for Health Policy, Duke University, Washington, DC, USA; Rachael Fleurence, PhD, Program Director of Comparative Effectiveness Research Methods and Infrastructure Program, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Catherine A. Panozzo, PhD, MPH, Instructor, Department of Population Medicine, Harvard Pilgrim Health Care Institute/Harvard Medical School, Boston, MA, USA

CLINICAL OUTCOMES RESEARCH

W4: THE SCIENCE AND ART OF PERFORMING NETWORK META-ANALYSES (NMA) TO AID DECISION MAKING FOR TYPE 2 DIABETES TREATMENT: HOW DOES IT WORK IN PRACTICE? Georgetown (Concourse Level)
Discussion Leaders: Keith Abrams, PhD, Professor of Medical Statistics, Health Sciences, University of Leicester, Leicester, UK; Robert Cuddihy, MD, Vice President, Global Medical Affairs CVM, Janssen Global Services, LLC, Raritan, NJ, USA; Melanie Schroeder, MSc, Outcomes Research Associate, Janssen-Cilag UK, High Wycombe, UK; Maud Pacou, BSc, Team Leader, Statistics, Amaris, Paris, France

ECONOMIC OUTCOMES RESEARCH

W5: CONSTRAINED OPTIMIZATION: WHY MAKING PIZZA AND MAXIMIZING HEALTH CARE VALUE ARE THE SAME PROBLEM Lincoln (Concourse Level)
Discussion Leaders: Kalyan Pasupathy, PhD, Associate Professor, Health Care Policy & Research, Mayo Clinic, Rochester, MN, USA; William Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA; Jonathan C. Tosh, PhD, Senior Health Economist, DRG Abacus, Manchester, England, UK; Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research & Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

W6: EQUIVALENCE OF PAPER AND ELECTRONIC MODES OF PATIENT-REPORTED OUTCOME DATA COLLECTION: AN ANSWERED QUESTION Jefferson (Concourse Level)
Discussion Leaders: Jason Lundy, PhD, Principal, Outcometrix, Tucson, AZ, USA; Paul O’Donohoe, MSc, Director, Health Outcomes, CRF Health, London, UK; Stephen Joel Coons, PhD, Executive Director, PRO Consortium, Critical Path Institute, Tucson, AZ, USA

W7: EXPLORING AND LEVERAGING KNOWN RESOURCES TO SUPPORT PEDIATRIC CLINICAL OUTCOMES ASSESSMENT (COA) DEVELOPMENT Monroe (Concourse Level)
Discussion Leaders: Diane M. Turner-Bowker, PhD, Director, Patient-Centered Outcomes, Adelphi Values, Boston, MA, USA; Meaghan Krohe, PhD, Associate Director, Patient-Centered Outcomes, Adelphi Values, Boston, MA, USA; Christine Archuleta Banderas, MA, CCLS, Child Life Specialist, Mattel Children’s Hospital, UCLA, Los Angeles, CA, USA

6:00PM-7:45PM EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II Columbia & Intl Terrace (Terrace Level) and Concourse Lobby
Reception Sponsored by Evidera
F1: ISSUES TO ADDRESS IN REVISIONING THE ISPOR CODE OF ETHICS

**Intl Ballroom West (Entrance-Terrace Level)**

Presented by the ISPOR Code of Ethics Task Force

**Moderator:** Francis Palumbo, PhD, JD, Professor, School of Pharmacy, University of Maryland, Baltimore, MD, USA

**Speakers:** Jessica Santos, PhD, Global Compliance and Quality Director, Kantar Health, Epsom, UK; David Thompson, PhD, Senior Vice President, Real World Evidence Consulting, inVentivHealth, Burlington, MA, USA; Louise Binder, Health Policy Consultant, Canadian Cancer Survivor Network, Toronto, ON, Canada; Richard J. Willke, PhD, Chief Science Officer, ISPOR, Lawrenceville, NJ, USA

F2: CLINICAL OUTCOMES ASSESSMENT (COA) MEASUREMENT IN RARE DISEASE CLINICAL TRIALS – A CASE STUDY ON APPLICATION OF EMERGING GOOD PRACTICES

**Intl Ballroom East (Concourse Level)**

Presented by the ISPOR COA Measurement in Rare Disease Clinical Trials Task Force

**Moderator:** Katy Benjamin, PhD, MS, Director, Patient Reported Outcomes, ICON, Bethesda, MD, USA

**Speakers:** Laurie Burke, MPH, RPh, Founder, LORA Group, Royal Oak, MI, USA; Donald L. Patrick, PhD, MSPH, Director, Seattle Quality of Life Group and Biobehavioral Cancer Prevention and Training Program, University of Washington, Seattle, WA, USA; Margaret K. Vernon, PhD, Senior Research Scientist, Evidera, London, UK

F3: STATISTICAL ANALYSIS OF DISCRETE-CHOICE EXPERIMENTS: A DISCUSSION OF THE ISPOR CONJOINT ANALYSIS GOOD RESEARCH PRACTICES TASK FORCE REPORT

**Intl Ballroom Center (Entrance-Terrace Level)**

Presented by the ISPOR Conjoint Analysis Good Research Practices Task Force

**Moderator:** Maarten J. Uizerman, PhD, Full Professor, Epidemiology & HTA & Dean, Health and Biomedical Technology, School for Science and Technology, University of Twente, Enschede, The Netherlands

**Speakers:** John F.P. Bridges, PhD, Associate Professor, Department of Health Policy and Management and International Health, John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Juan Marcos Gonzalez, PhD, Senior Research Economist, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research & Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

F4: ECONOMIC EVALUATION OF VACCINES

**Jefferson (Concourse Level)**

Presented by the ISPOR Economic Evaluation of Vaccines Designed to Prevent Infectious Disease: Good Practices Task Force

**Moderator:** Baudouin Standaert, MD, PhD, Health Economics, GlaxoSmithKline Vaccines, Wavre, Belgium

**Speakers:** Josephine A. Mauskopf, PhD, MHA, MA, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA; Johan L. Severens, PhD, Professor of Evaluation in Health Care, Institute of Health Policy & Management, Institute of Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands

F5: FIT FOR PURPOSE: PREPARING FOR A PROFESSIONAL CAREER

**Lincoln (Concourse Level)**

Presented by the ISPOR Student Council

**Moderator:** Zeba M. Khan, RPh, PhD, Vice President, Celgene Corporation, Summit, NJ, USA

**Speakers:** Jacquelyn McNair, PharmD, Health Economics and Outcomes Research Fellow, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA, USA; Annesha White, PharmD, MS, PhD, Assistant Professor, College of Pharmacy, University of North Texas, Fort Worth, TX, USA; Joseph Pandigo, MBA, MS, Director, Policy & Research, PhRMA, Washington, DC, USA; Selena Daniels, PharmD, Study Endpoints Reviewer, SEALD, U.S. Food and Drug Administration, Silver Spring, MD, USA; Abhishek Chitnis, MPH, Associate Director, Johnson & Johnson, Raynham, MA, USA

F6: PATIENT-CENTERED HEALTH CARE IN THE BRICS COUNTRIES

**Georgetown (Concourse Level)**

Presented by ISPOR BRICS

**Moderator:** Jitendar Sharma, PhD, Head, WHO Collaborating Centre for Priority Medical Devices & Health Technology Policy, NIHSCR, New Delhi, India

**Speakers:** Pavel A. Vorobiev, MD, MSc, PhD, Chair of Haematology and Geriatrics, I. M. Sechenov First Moscow State Medical University, Moscow, Russian Federation; Gabriela Tannus, MBA, MSc, Owner & Health Economics Director, Axxia.Bio Group, Miami, FL, USA; Kun Zhao, MD, PhD, Professor & Director, Division of Health Technology Assessment, China National Health Development, Research Center, National Health and Family Planning Commission (NHFPC), Beijing, China; Shelley McGee, BPharm, BEd, M Health Ec, Healthcare Policy and Patient Access Manager, Sanofi Pharmaceuticals, Pretoria, South Africa

F7: MOVING TOWARDS AN INTEGRAL APPROACH TO PATIENTS WITH RARE DISEASES: AN INTERNATIONAL PERSPECTIVE

**Monroe (Concourse Level)**

Presented by the ISPOR Colombia Regional Chapter

**Moderator:** Hector Castro, MD, PhD, Postdoctoral Fellow, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA

**Speakers:** Giacomo Balbinotto Neto, PhD, Professor of Health Economics, Programa de Pós-Graduação em Economia (PPGE), Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil; Camila Quirland, DPharm, MSc, Researcher, Escuela de Salud Pública, Universidad de Chile, Santiago, Chile; Diego Rosselli, MD, MEd, MSc, Professor of Health Economics, Clinical Epidemiology and Biostatistics, Medical School, Pontificia Universidad Javeriana, Bogota, Colombia
Tuesday, May 24

7:15AM-8:15AM  **EDUCATIONAL SYMPOSIUM**  *Jefferson (Concourse Level)*
**DRIVERS OF EFFECTIVENESS FOR INFORMED OUTCOMES-BASED AGREEMENTS**
Sponsored by LASER ANALYTICA

8:30AM-2:00PM  **RESEARCH POSTER PRESENTATIONS - SESSION III**  *Columbia (Terrace Level)*

8:30AM-10:30AM  **WELCOME & SECOND PLENARY SESSION**  *Intl Ballroom (Entrance-Terrace Level)*

**WELCOME FROM ISPOR PRESIDENT**
Daniel Malone, PhD, RPh, 2015-2016 ISPOR President, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

**WELCOME FROM ISPOR CHIEF SCIENCE OFFICER**
Richard J. Willke, PhD, Chief Science Officer, ISPOR, Lawrenceville, NJ, USA

**INCOMING PRESIDENTIAL ADDRESS**
Lou Garrison, PhD, 2015-2016 ISPOR President-Elect and Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA

**2016 ISPOR MARILYN DIX SMITH LEADERSHIP AWARD**
*Presented by:* Scott D. Ramsey, MD, PhD, Chair, ISPOR Marilyn Dix Smith Leadership Award Committee
**AWARDEE:** J. Jaime Caro, MDCM, FRCP, FACP, Chief Scientist, Evidera, Lexington, MA, USA and Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada

**2016 ISPOR AWARD FOR VALUE IN HEALTH PAPER OF THE YEAR**
*Announced by:* Michael Drummond, PhD, and C. Daniel Mullins, PhD, *Value in Health* Co-Editors-in-Chief
**AWARDEE:** Ethan Basch, MD, MSc, Cancer Outcomes Research Program, University of North Carolina, Chapel Hill, NC, USA
2016 ISPOR VALUE IN HEALTH REGIONAL ISSUES EXCELLENT ARTICLE AWARD
Presented by: Federico Augustovski, MD, MSc, PhD, Value in Health Regional Issues Co-Editor-in-Chief
AWARDEE: Mônica Viegas Andrade, PhD, Associate Professor, Universidad Federal de Minas Gerais, Belo Horizonte, Brazil & Harvard School of Public Health, Boston, MA, USA

2016 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
Presented by: Federico Augustovski, MD, MSc, PhD, Chair, ISPOR Award for Excellence in Methodology of Pharmacoeconomics and Health Outcomes Research Committee
AWARDEE: Anirban Basu, PhD, Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, Departments of Health Services and Economics, University of Washington, Seattle, WA, USA

2016 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
Presented by: Dan Greenberg, PhD, Chair, ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Committee
AWARDEE: Joshua J. Gagne, PharmD, ScD, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

2016 ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARD
Presented by: Jalpa Doshi, PhD, Chair, ISPOR Bernie O’Brien New Investigator Award Committee
AWARDEE: Anthony Newall, PhD, Senior Lecturer, UNSW Australia, School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia

SECOND PLENARY SESSION: MAKING MEDICAL DECISIONS IN AN IRRATIONAL WORLD
Frameworks such as decision- and cost-effectiveness analyses to guide resource allocation options are grounded in neo-classical economic theory based on rational choice under uncertainty. Over the past four decades, there is increasing biologic and experimental evidence suggesting that these underpinnings are inconsistent with human preferences and behaviors. This session will present emerging behavioral economic models and findings and discuss how they will influence the design of health plans and methods for incorporating preferences.
Moderator: Bradley C. Martin, PharmD, RPh, PhD, Professor & Head, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA
Speakers:
Kevin Volpp, MD, PhD, Director, Center for Health Incentives and Behavioral Economics, Leonard Davis Institute, Vice Chair, Health Policy, Department of Medical Ethics, and Health Policy Professor, Medicine and Health Care Management, University of Pennsylvania, Philadelphia, PA, USA
Douglas E. Hough, PhD, Associate Scientist, Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
David Meltzer, MD, PhD, Fannie L. Pritzker Professor of Medicine, Economics, and Public Policy, Chief of the Section of Hospital Medicine, Director of the Center for Health and the Social Sciences, and Chair of the Committee on Clinical and Translational Science, University of Chicago, Chicago, IL, USA

10:30AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III Columbia & Intl Terrace (Terrace Level) and Concourse Lobby
Coffee Break Sponsored by Analysis Group
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP6: MULTI-INDICATION PRICING: DO WE WANT IT? CAN WE OPERATIONALIZE IT?

Intl Ballroom Center (Entrance-Terrace Level)

Moderator: Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK
Panelists: Bill Dreitlein, PharmD, Director of Pharmaceutical Policy, Institute for Clinical and Economic Review, Boston, MA, USA; Sean Karbowicz, PharmD, Director, Innovation and Pharmacy Policy, OmedaRx, Portland, OR, USA; Ansgar Hebborn, PhD, Head, Global HTA & Payment Policy, Global Pricing & Market Access, F. Hoffmann-La Roche AG, Basel, Switzerland

IP7: PHARMACEUTICAL PRICING IN THE UNITED STATES: ARE WE BALANCING INNOVATION AND AFFORDABILITY?

Intl Ballroom West (Entrance-Terrace Level)

Moderator: Dana Goldman, PhD, Leonard D. Schaeffer Director’s Chair, Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA
Panelists: Tomas Philipson, PhD, Daniel Levin Professor of Public Policy Studies, Irving B. Harris Graduate School of Public Policy Studies, University of Chicago, Chicago, IL, USA; Dan Ollendorf, PhD, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA

USE OF REAL WORLD DATA ISSUES

IP8: INCORPORATING REAL-WORLD EVIDENCE FOR REGULATORY DECISION MAKING: IS THE DEVICE ECOSYSTEM READY?

Intl Ballroom East (Concourse Level)

Moderator: Danica Marinac-Dabic, MD, PhD, Director, Division of Epidemiology, CDRH, U.S. Food and Drug Administration, Silver Spring, MD, USA
Panelists: Gerry Gray, PhD, Acting Director, Division of Biostatistics, CDRH, U.S. Food and Drug Administration, Silver Spring, MD, USA; Sharon-Lise T. Normand, PhD, Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA; Richard Kuntz, MD, MSC, Chief Medical and Regulatory Officer, Medtronic, Minneapolis, MN, USA

CLINICAL OUTCOMES RESEARCH ISSUES

IP9: NEXT GENERATION COMPARATIVE EFFECTIVENESS RESEARCH – ARE WE GETTING ORGANIZED TO FACILITATE RESEARCH FOR THE INDIVIDUAL PATIENT?

Jefferson (Concourse Level)

Moderator: Kristian Thorlund, PhD, MSc, Vice President of Health Analytics, Precision Health Economics, Vancouver, BC, Canada
Panelists: Rachael Fleurence, PhD, Program Director of Comparative Effectiveness Research Methods and Infrastructure Program, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Sonal Singh, MBBS, MPH, Assistant Professor, Johns Hopkins Medicine, Baltimore, MD, USA; Anupam Jena, MD, PhD, Associate Professor of Health Care Policy and Medicine, Harvard Medical School and Attending Physician, Massachusetts General Hospital, Boston, MA, USA

ECONOMIC OUTCOMES RESEARCH ISSUES

IP10: COST-EFFECTIVENESS THRESHOLDS: SHOULD WE BE GENERATING MORE EMPIRICAL EVIDENCE AND, IF SO, HOW?

Lincoln (Concourse Level)

Moderator: Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics & Director, Programme on Economic Evaluation and Health Technology Assessment, University of York, Harlington, York, UK
Panelists: Federico Augustovski, MD, Director, Health Technology Assessment and Health Economic Department, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; Marta Soares, MSC, Senior Research Fellow, Team for Economic Evaluation and Health Technology Assessment (TEEHTA), Centre for Health Economics, University of York, Harlington, York, UK; Anirban Basu, PhD, Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

12:00PM-2:15PM

LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III

Columbia & Intl Terrace (Terrace Level) and Concourse Lobby

Lunch Sponsored by RTI Health Solutions

12:30PM-1:30PM

EDUCATIONAL SYMPOSIUM

Intl Ballroom East (Concourse Level)

VALUE-BASED CONTRACTING FOR PHARMACEUTICALS: DRIVING VALUE AND QUALITY OF CARE

Sponsored by Optum
### Program & Schedule of Events: Tuesday, May 24

#### 12:45PM-1:15PM
**New Member and First-Time Attendee Welcome**  
Georgetown (Concourse Level)
Join us to meet ISPOR’s President Dan Malone, Incoming President Lou Garrison, and CEO Nancy Berg. The Board of Directors and ISPOR staff will be available to share information about member benefits and volunteer opportunities.

#### 1:00PM-2:00PM
**Poster Author Discussion Hour - Session III**  
Columbia (Terrace Level)

#### 1:15PM-2:00PM
**ISPOR General Business Meeting**  
Georgetown (Concourse Level)
Members are invited to attend ISPOR’s General Business Meeting, the official business meeting of the Society. Members will learn about ISPOR’s recent accomplishments and plans for the future and have the opportunity to meet Board members. Highlights from the recent Chapter Survey and Member Survey will also be presented.

#### 2:15PM-3:15PM
**Issue Panels - Session III**

**Health Policy Development Using Outcomes Research Issues**

**IP11: How Do Culture, Values, and Institutional Context Shape the Methods and Use of Economic Evaluation?**  
Intl Ballroom Center (Entrance-Terrace Level)
- **Moderator:** Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
- **Panelists:** Aleksandra Torbica, PhD, Professor, Bocconi University, Milano, Italy; Peter J. Neumann, ScD, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Robert W Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA

**IP12: Multi-Criteria Decision Analysis: A New Paradigm in Health Care Decision Making? What Are the Current Status, Challenges, and Opportunities?**  
Jefferson (Concourse Level)
- **Moderator:** James Dolan, MD, Professor, University of Rochester, Rochester, NY, USA
- **Panelists:** Kevin Marsh, PhD, Executive Director, Evidera, London, UK; Mireille M. Goetghebeur, PhD, MEng, Global Scientist, LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada; Mabel Moreno Viscaya, PhD, Senior Economist, Instituto de Evaluación Tecnológica en Salud (IETS), Bogota, Colombia

**IP13: Performance-Based Risk-Sharing Arrangements: What Are the Views From the Negotiating Table?**  
Intl Ballroom West (Entrance-Terrace Level)
- **Moderator:** Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA
- **Panelists:** Michael L. Ryan, PharmD, Senior Vice President, Bristol-Myers Squibb, Princeton, NJ, USA; Michael S. Sherman, MD, MBA, MS, Senior Vice President & Chief Medical Officer, Harvard Pilgrim Health Care, Wellesley, MA, USA; Jim Clement, MHA, Executive Director, Industry Relations & Financial Strategy, Aetna, Hartford, CT, USA

**IP14: The Value of Specialty Drugs: Can We Develop Novel Access Policies for Novel Medicines?**  
Intl Ballroom East (Concourse Level)
- **Moderator:** Tomas Philipson, PhD, Daniel Levin Professor of Public Policy Studies, Irving B. Harris Graduate School of Public Policy Studies, University of Chicago, Chicago, IL, USA
- **Panelists:** Anupam Jena, MD, PhD, Associate Professor of Health Care Policy and Medicine, Harvard Medical School and Attending Physician, Massachusetts General Hospital, Boston, MA, USA; Darius N. Lakdawalla, PhD, Professor, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, University of Southern California, Los Angeles, CA, USA; Wade Aubry, MD, Associate Clinical Professor of Medicine, Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, CA, USA

**Use of Real World Data Issues**

**IP15: Social Listening for Safety Outcomes and Pharmacoeconomic Considerations: Has the Time Come?**  
Lincoln West (Concourse Level)
- **Moderator:** Marilyn A. Metcalf, PhD, Director, GCSP, GlaxoSmithKline, Research Triangle Park, NC, USA
- **Panelists:** Amir Lewkowicz, MBA, Vice President, Strategic Partnerships, Inspire, Arlington, VA, USA; Robert Ball, MD, MPh, Deputy Director, Office of Surveillance and Epidemiology, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA; Nabarun Dasgupta, MPh, PhD, Chief Product Officer, Epidemico, Boston, MA, USA

#### 3:15PM-3:45PM
**Break & Exhibits Viewing**  
Columbia & Intl Terrace (Terrace Level) and Concourse Lobby
Coffee Break Sponsored by Covance Inc.
3:45PM-4:45PM | WORKSHOPS - SESSION II

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH

**W8: ESTABLISHING THE VALUE OF DIAGNOSTIC AND PROGNOSTIC TOOLS IN HEALTH TECHNOLOGY ASSESSMENT**  
*Monroe (Concourse Level)*

**Discussion Leaders:**  
Susan Griffin, PhD, MSc, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK;  
Marta Soares, MSc, Senior Research Fellow, Team for Economic Evaluation and Health Technology Assessment (TEEHTA), Centre for Health Economics, University of York, Heslington, York, UK;  
Andrew Briggs, DPhil, MSc, Visiting Investigator, Center for Health Policy and Outcomes, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA and William R. Lindsey Chair of Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK;  
Manuel Antonio Espinoza, MD, MSc, PhD, Professor of Public Health, Centro de Investigacion Clinica UC, Pontificia Universidad Catolica de Chile, Santiago, Chile

**W9: FIVE YEARS OF HEALTH CARE HORIZON SCANNING FOR AHRQ – RESULTS AND LESSONS LEARNED**  
*Intl Ballroom West (Entrance-Terrace Level)*

**Discussion Leaders:**  
Elise Berliner, PhD, Director, Technology Assessment, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, MD, USA;  
Karen Schoelles, MD, SM, Director, ECRI Institute-Penn Medicine Evidence-based Practice Center, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA;  
Diane Robertson, BA, Director, ECRI Institute Health Technology Assessment Information Service, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA;  
Marcus Lynch, PhD, Senior Clinical Writer, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA

USE OF REAL WORLD DATA

**W10: REAL-WORLD DATA AND REAL-WORLD EVIDENCE IN LATIN AMERICA: IT TAKES TWO TO TANGO**  
*Georgetown (Concourse Level)*

**Discussion Leaders:**  
Marcelo Eidi Nita, MD, MSc, PhD, Lecturer & Researcher in HTA and PCDT, IECs, HAOC, and FIPE, Sao Paulo, Brazil;  
Paulo Vaz, PhD, CEO, HEADS, Sao Paulo, Brazil;  
André Ferraz, PhD, Real-World Evidence Solutions, Latin America, IMS Health, Sao Paulo, Brazil;  
David Thompson, PhD, Senior Vice President, inVentiv Health, Burlington, MA, USA

CLINICAL OUTCOMES RESEARCH

**W11: SPECIALTY DRUGS REQUIRE SPECIALTY METHODS: MAXIMIZING THE VALUE OF ADMINISTRATIVE CLAIMS FOR SPECIALTY DRUG OUTCOMES & POLICY RESEARCH**  
*Lincoln West (Concourse Level)*

**Discussion Leaders:**  
Jalpa A. Doshi, PhD, Associate Professor of Medicine, Director, Economic Evaluations Unit, Center for Evidence-Based Practice, and Director, Value-Based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, General Internal Medicine, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA;  
Yu-Ning Wong, MD, MD, MSCE, Associate Professor, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA;  
Salim Chahin, MD, MSCE, Instructor, Neurology, University of Pennsylvania Health System, Philadelphia, PA, USA;  
Scott Huntington, MD, MPH, MSc, Assistant Professor of Medicine, Yale School of Medicine & Yale School of Public Health, Yale University, New Haven, CT, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

**W13: PATIENTS AS PARTNERS IN RESEARCH – MAKING IT A REALITY**  
*Jefferson (Concourse Level)*

**Discussion Leaders:**  
Rachel Harrington, PhD, Senior Research Alliances Manager, Health Economics and Clinical Outcomes Research, Astellas Medical Affairs Americas, Northbrook, IL, USA;  
Alfonso Aguaron, Project Manager, Myeloma Patients Europe, Madrid, Spain;  
Robert N. McBurney, PhD, Chief Executive Officer, Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, USA;  
Holly Peay, PhD, MS, CGC, Principal Investigator, DuchenneConnect Network, Parent Project Muscular Dystrophy, and Research Scientist, RTI International, Research Triangle Park, NC, USA

**W14: CHOICE DEFINES VALUE: PATIENT PREFERENCES AND MULTI-CRITERIA DECISION ANALYSIS ARE KEY FOR ANY EVIDENCE-BASED APPRAISAL PROCESS IN HEALTH TECHNOLOGY ASSESSMENT**  
*Intl Ballroom East (Concourse Level)*

**Discussion Leaders:**  
Axel Mühlbacher, PhD, Professor, Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany;  
Juan Manuel Ramos-Goñi, MSc, Research Scientist, The EuroQol Research Foundation, Rotterdam, The Netherlands;  
Benjamin M. Craig, PhD, Associate Professor of Economics, University of South Florida, Tampa, FL, USA
Are you interested in publishing papers in or contributing to *Value in Health Regional Issues* (ViHRI) focusing on Asia, Latin America, and Central & Eastern Europe, Western Asia and Africa (CEEWAA)? Come to learn about this ISPOR scientific journal and directly ask the Editors about the scope of articles, publishing, review process, and other related topics.

SPECIAL BRIEFING ON THE ZIKA VIRUS: LEADING BRAZILIAN HEALTH AUTHORITIES & ACADEMICS REPORT

Zika virus is an emerging mosquito-borne virus with no specific treatment or vaccine currently available. A total of 59 countries as well as the World Health Organization are fighting against this global emergency. This ISPOR Brazil Chapter Special Briefing will highlight the current status on developments related to the Zika Virus and ways in which Brazil, the country that first reported a Zika virus disease, is leading major studies and interventions. Additionally, ways in which the global health community can partner to stop Zika will be presented. This open meeting will provide an opportunity for participants to discuss issues and challenges within this topic and develop HEOR projects at ISPOR and in their own countries. ISPOR members interested in Zika-related projects are welcome to attend.

USE OF REAL WORLD DATA

- **W16: VISUALIZING DATA FOR HYPOTHESIS GENERATION USING LARGE-VOLUME HEALTH CARE CLAIMS DATA**
  - **Jefferson (Concourse Level)**
  - Discussion Leaders: Eberechukwu Onukwugha, MS, PhD, Associate Professor, Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD, USA; Margret Bjarnadottir, PhD, Assistant Professor, Smith School of Business, University of Maryland, College Park, MD, USA; Shujia Zhou, PhD, Research Associate Professor, Computer Science and Electrical Engineering, University of Maryland, Baltimore, MD, USA

**USE OF REAL WORLD DATA**

**W17: MEDICAL DEVICE EVALUATIONS VIA COORDINATED REGISTRY NETWORKS: ANALYTICAL AND INFRASTRUCTURE CONSIDERATIONS**

- **Intl Ballroom West (Entrance-Terrace Level)**
- **Discussion Leaders:** Sharon-Lise T. Normand, PhD, Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA; Danica Marinac-Dabic, MD, PhD, Director, Division of Epidemiology, CDRH, U.S. Food and Drug Administration, Silver Spring, MD, USA; Art Sedrakyan, MD, PhD, Professor, Weill Cornell Medical College, New York, NY, USA

ECONOMIC OUTCOMES RESEARCH

**W18: PREDICTING MARKET OUTLOOK: ENHANCING MARKET FORECASTING VIA APPLICATION OF PHARMAECOEMONOMIC MODELING TECHNIQUES**

- **Lincoln West (Concourse Level)**
- **Discussion Leaders:** Baris Deniz, MSc, Senior Research Scientist, Modeling & Simulation, Evidera, Bethesda, MD, USA; Sean Stern, MSc, Research Associate, Modeling & Simulation, Evidera, Bethesda, MD, USA; Steven Peterson, MSc, Director, Janssen, Horsham, PA, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

**W19: PATIENT-CENTERED BENEFIT-RISK ANALYSIS: REGULATORY DEVELOPMENTS AND PROSPECTS**

- **Intl Ballroom East (Concourse Level)**
- **Discussion Leaders:** Bryan Luce, PhD, MBA, Senior Advisor, Evidera, Bethesda, MD, USA; Martin Ho, PhD, MS, Team Leader, Neurologic and Dental Biostatistics, U.S. Food and Drug Administration, Silver Spring, MD, USA; Jason Gerson, PhD, Associate Director, CER Methods, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Sara Eggers, PhD, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
W20: A FRAMEWORK FOR MEASURING MULTIPLE MEDICATION ADHERENCE  
**Georgetown (Concourse Level)**  
**Discussion Leaders:** Thomas J. Bunz, PharmD, PhD, Director of Analytic Strategy, Aetna Consumer Analytics, Granby, CT, USA; Maria Malmenäs, MSc, Director, HEMU, PAREXEL International, Stockholm, Sweden; Tamas Agh, MD, PhD, Principal Researcher, Syreon Research Institute, Budapest, Hungary; Priti Pednekar, MPharm, Graduate Student, Mayes College of Healthcare Business and Policy, University of the Sciences, Philadelphia, PA, USA

W21: EMPOWERING PATIENT POPULATIONS WITH PHYSICAL OR COGNITIVE LIMITATIONS THROUGH ELECTRONIC CLINICAL OUTCOME ASSESSMENTS (ECOAS)  
**Monroe (Concourse Level)**  
**Discussion Leaders:** Chloe Tolley, BSc, Senior Research Manager, PCO, Adelphi Values Ltd, Bollington, UK; Paul O’Donohoe, MSc, Director, Health Outcomes, CRF Health, London, UK; Jessica L. Abel, MPH, Manager, Global Health Economics and Outcomes Research, Allergan plc., Jersey City, NJ, USA

6:00PM-7:45PM  
**EXHiBiTors’ wiNE & CHEEsE rECEpTioN & rEsEArCH posTEr prEsENTATioNs ViEwiNg - sEssioN iV**  
**Columbia & Intl Terrace (Terrace Level) and Concourse Lobby**  
Reception Sponsored by Quintiles  
Dessert Table Sponsored by PhRMA Foundation

6:15PM-7:15PM  
**ISPOR FORUMs - SESSION II**

F8: DEVELOPING AND EVALUATING CLINICIAN-REPORTED OUTCOMES (CLINROS) – A CASE STUDY ON APPLICATION OF EMERGING GOOD PRACTICES  
**Intl Ballroom East (Concourse Level)**  
**Presented by the ISPOR Clinical Outcomes Assessment – Emerging Good Practices Task Force**  
**Moderator:** John Powers, MD, Associate Clinical Professor of Medicine, School of Medicine Penfield House, George Washington University, Rockville, NJ, USA  
**Speakers:** Laurie B. Burke, RPh, MPH, Founder, Lora Group, LLC, and Former Director, Study Endpoints and Labeling Development, ONDIO, CDER, U.S. Food & Drug Administration, Silver Spring, MD, USA; Donald L. Patrick, PhD, MSPH, Director, Seattle Quality of Life Group and Biobehavioral Cancer Prevention and Training Program, University of Washington, Seattle, WA, USA; Marc Walton, MD, Senior Scientific Director, Janssen Research and Development, Ashton, MD, USA

F9: THE DO’S AND DON’TS OF PERFORMING A SCOPING REVIEW  
**Lincoln West (Concourse Level)**  
**Moderator:** Karen Freyer, PhD, Nutritionist & Nutrition Economist, School for Public Health and Primary Care (CAPHRI), Maastricht University, Zoetermeer, The Netherlands  
**Speakers:** Sheri Volger, MS, Principal Clinical Scientist, Nestle Nutrition R&D, King of Prussia, PA, USA; Janos G. Pitter, MD, PhD, Principal Researcher, Syreon Research Institute, Budapest, Hungary

F10: USE AND MANAGEMENT OF BIG DATA IN HEALTH ECONOMICS AND OUTCOMES RESEARCH FOR CREATING BEST PRACTICES IN ASIA-PACIFIC: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN, SINGAPORE, SOUTH KOREA, AND TAIWAN  
**Jefferson (Concourse Level)**  
**Presented by the ISPOR Asia Consortium**  
**Moderator:** Hwee Lin Wee, PhD, BSc(Pharm)Hons, Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore  
**Speakers:** Seungjin Bae, PhD, Associate Professor, Pharmacoconomics and Outcomes Research, College of Pharmacy, Ewha Womans University, Seoul, South Korea; Bruce Crawford, MA, MPH, Senior Principal, Real-World Evidence Solutions, Japan & APAC, IMS Japan K.K., Minato-ku, Tokyo, Japan; Libby Roughhead, PhD, Director & Research Professor, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, SA, Australia; Chee-Jen Chang, PhD, Director & Professor, Clinical Informatics and Medical Statistics Research Center, Chang Gung University, TaoYuan, Taiwan

F11: PUBLIC ENGAGEMENT IN HEALTH CARE PRIORITY SETTING: EXPERIENCES AND CHALLENGES AT ENGAGING THE PUBLIC IN LATIN AMERICA  
**Lincoln East (Concourse Level)**  
**Presented by the ISPOR Latin America Consortium News Across Latin America Editorial Board**  
**Moderator:** Yajaira M. Bastardo, PhD, Professor, Pharmacoconomics, Central University of Venezuela, Caracas, Venezuela  
**Speakers:** Aline Silveira Silva, MS, Technologist, Executive Secretariat, CONITEC, Brazilian Ministry of Health, Brasilia, Brazil; Jennifer Whitty, PhD, Professor of Health Economics, University of East Anglia, Norwich, UK; Diego Rosselli, MD, MEd, MSc, Professor of Health Economics, Clinical Epidemiology and Biostatistics, Medical School, Pontificia Universidad Javeriana, Bogota, Colombia
F12: VALUE IN HEALTH FORUM ON PATIENT-FOCUSED BENEFIT-RISK ANALYSIS TO INFORM REGULATORY DECISIONS

Intl Ballroom West (Entrance-Terrace Level)

Presented by the Value in Health Editorial Board

Moderator: Shelby Reed, PhD, RPh, Associate Professor in Medicine, Duke Clinical Research Institute, Durham, NC, USA

Speakers: Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research & Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada; F. Reed Johnson, PhD, Senior Research Scholar, Preference Evaluation Research Group, Duke Clinical Research Institute, Durham, NC, USA; Axel C. Muhlbacher, PhD, Professor, Hochschule Neubrandenburg, Neubrandenburg, Germany; Bennett Levitan, MD, PhD, Senior Director, Benefit-Risk Assessment, Epidemiology, Janssen Research & Development, LLC, Titusville, NJ, USA

F13: DEVELOPMENT AND APPLICATION OF MULTI-CRITERIA DECISION ANALYSIS IN CENTRAL & EASTERN EUROPE (CEE) IN COOPERATION WITH WESTERN COUNTRIES

Monroe (Concourse Level)

Presented by the ISPOR CEE Network

Moderator: Natia Kvizhinadze, MD, PhD, President, ISPOR Georgia Chapter, Professor, Tbilisi State Medical University, Tbilisi, Georgia

Speakers: Oresta Piniazhko, MSPharm, PhD Candidate, & Assistant Professor, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine; Vladimir Zah, Health Economist, ZRx Outcomes Research Inc., Belgrade, Serbia; Lubov Krasnova, MD, PhD, Senior Researcher, Department of Hematology & Geriatrics, First Sechenov State Medical University, Moscow, Russian Federation; Tamás Ágh, MD, PhD, Principal Researcher, Syreon Research Institute, Budapest, Hungary

F14: THE HEALTH AND ECONOMIC THREATS OF NON-COMMUNICABLE DISEASES IN THE MIDDLE EAST AND NORTH AFRICA

Georgetown (Concourse Level)

Presented by the ISPOR Arabic Network

Moderator: Daoud Al-Badriyeh, PhD, President, ISPOR Qatar Chapter and Assistant Professor, Qatar University, Doha, Qatar

Speakers: Abdulaziz H. Al-Saggabi, MSc, PharmD, President, ISPOR Saudi Arabia Chapter and Director, Drug Policy & Economics Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia; Ola G. Al Ahdab Albannay, PhD, PGD, RPh, President, ISPOR United Arab Emirates Chapter and Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates; Mahmoud Diaa Elmahdawy, PharmD, President, ISPOR Egypt Chapter, Director, AMAC Market Access, Novartis, Health Economics, Lecturer of Clinical and Hospital Pharmacy, Misr International University, Cairo, Egypt; Christiane Maskineh, DBA (c) and Executive Director, ISPOR Lebanon Chapter, Beirut, Lebanon

Wednesday, May 25

8:30AM-1:30PM RESEARCH POSTER PRESENTATIONS - SESSION V

Columbia (Terrace Level)

8:30AM-9:30AM ISSUE PANELS - SESSION IV

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES

IP16: ARE ALTERNATIVE FINANCING APPROACHES NEEDED FOR INNOVATIVE THERAPIES?

Georgetown (Concourse Level)

Moderator: Noam Y. Kirson, PhD, Vice President, Analysis Group, Inc., Boston, MA, USA

Panelists: Mike Ciarametaro, MBA, Director of Research, National Pharmaceutical Council, Washington, DC, USA; John Michael O’Brien, PharmD, MPH, Vice President, Public Policy, CareFirst BlueCross BlueShield, Washington, DC, USA; Krista M. Ward, MBA, Senior Director, Medicaid, Express Scripts, St. Louis, MO, USA

IP17: HARNESSING BIG DATA FOR WOUND HEALING RESEARCH: WHICH IS MORE RELEVANT IN THE QUEST FOR EVIDENCE – REAL-WORLD PATIENT-CENTERED OUTCOMES OR RANDOMIZED TRIALS?

Jefferson East (Concourse Level)

Moderator: Marcia Nusgart, RPh, Executive Director, Alliance of Wound Care Stakeholders, Bethesda, MD, USA

Panelists: Elise Berliner, PhD, Director of the Technology Assessment Program, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA; Caroline E. Fife, MD, Professor of Geriatrics, Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA; Marissa J. Carter, PhD, MA, President, Strategic Solutions Inc., Cody, WY, USA
IP18: PRECISION MEDICINE: THE END OF OUTCOMES RESEARCH?  
**Moderator:** Fadia T. Shaya, PhD, MPH, Professor, Associate Director, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
**Panelists:** John Watkins, PharmD, MPH, BCPS, Formulary Manager, Premera Blue Cross, Mountlake Terrace, WA, USA; Susan Snyder, PhD, MBA, Research Investigator & Health Economist, Center for Health Research, Geisinger Health System, Danville, PA, USA

**CLINICAL OUTCOMES RESEARCH ISSUES**

IP19: CREATING AND ANALYZING SYMPTOM ENDPOINTS WHEN THERE IS SYMPTOM HETEROGENEITY ACROSS PATIENTS: WHAT ARE THE POTENTIAL SOLUTIONS?  
**Moderator:** Chad Gwaltney, PhD, Research Assistant Professor, Brown University, Providence, RI, USA
**Panelists:** Karon F. Cook, PhD, Research Professor, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Elekta Papadopoulos, MD, Acting Director, Clinical Outcome Assessments Staff, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA; Matthew Reaney, CPsychol, MSc, Senior Scientist, ERT, Peterborough, UK

**PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES**

IP20: WHAT IS THE VALUE OF VALUE FRAMEWORKS TO PATIENTS? THE CASE IN ONCOLOGY  
**Moderator:** Josh Seidman, PhD, Senior Vice President, Avalere Health, Washington, DC, USA
**Panelists:** Rob Hauser, PhD, PharmD, Vice President, Cancer Treatment Centers of America, Boca Raton, FL, USA; Eric Kruep, MS, PharmD, Outcomes Research Liaison, Novartis Pharmaceuticals, East Hanover, NJ, USA; Frederick May, MD, Medical Director, Educators Mutual Insurance, Indianapolis, IN, USA

**9:30AM-9:45AM  BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V  Columbia & Intl Terrace (Terrace Level) and Concourse Lobby**

**9:45AM-11:30AM  WELCOME & THIRD PLENARY SESSION  Intl Ballroom Center (Entrance-Terrace Level)**

**WELCOME FROM ISPOR PRESIDENT**
Daniel Malone, PhD, RPh, 2015-2016 ISPOR President, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

**ISPOR SERVICE AWARDS**
**Presented by:** Daniel Malone, PhD, RPh, 2015-2016 ISPOR President, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

**ISPOR STUDENT AWARDS**
**Presented by:** Zeba M. Khan, PhD, RPh, ISPOR Student Network Advisor and Vice President, Celgene Corporation, Summit, NJ, USA

**PhRMA FOUNDATION AWARDS**
**Presented by:** Eileen M. Cannon, President, PhRMA Foundation, Washington, DC, USA
THIRD PLENARY SESSION: CONTEMPORARY REGULATORY AND LEGISLATIVE ISSUES IN HEALTH OUTCOMES RESEARCH

This session is dedicated to a discussion of current regulatory and legislative issues affecting health outcomes research. Speakers from the U.S. Food and Drug Administration, the pharmaceutical industry, patient advocacy, and policy think tanks will address current issues surrounding health outcomes research, including patient-centered research and development, promotion of health economic claims, and role of regulatory oversight in a dynamic health care environment.

Moderator: Daniel Malone, PhD, RPh, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

Speakers:
- Theresa M. Mullin, PhD, Director, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA
- Marc M. Boutin, JD, Chief Executive Officer, National Health Council, Washington, DC, USA
- Gregory W. Daniel, PhD, MPH, RPh, Deputy Director, Duke-Robert J. Margolis, MD Center for Health Policy, Duke University, Washington, DC, USA
- Kay Holcombe, MS, Senior Vice President, Science Policy, BIO, Washington, DC, USA

11:30AM-11:45AM ISPOR 21st INTERNATIONAL MEETING RESEARCH PRESENTATION AWARDS  
(Entrance-Terrace Level)

ISPOR BEST PODIUM PRESENTATION AWARDS

Presented by: Carl V. Asche, MBA, MSc, PhD, Research Professor of Medicine & Director, Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL, USA

ISPOR BEST POSTER PRESENTATION AWARDS

Presented by: Rajender R. Aparasu, PhD, Professor & Department Chair, University of Houston, Houston, TX, USA

11:45AM-1:45PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V  
(Columbia & Intl Terrace (Terrace Level) and Concourse Lobby)

12:30PM-1:30PM POSTER AUTHOR DISCUSSION HOUR - SESSION V  
(Columbia (Terrace Level))

1:45PM-2:45PM WORKSHOPS - SESSION IV

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W22: THE OPPORTUNITY FOR USING PATIENT-CENTRIC, COMPARATIVE EFFECTIVENESS AND OUTCOMES RESEARCH DATA: EVOLVING APPROACHES TO VALUE DEMONSTRATION AND PRICING IN THE UNITED STATES  
Georgetown (Concourse Level)

Discussion Leaders: Sue Ellen J. Kline, PhD, MS, Principal Health Economist, Nucleus X Market Access, Warren, NJ, USA; Emily C. Freeman, MSc, PhD, Senior Research Scientist, Eli Lilly and Company, Indianapolis, IN, USA; Gil L’Italien, PhD, Adjunct Associate Professor, School of Medicine, Yale University, New Haven, CT, USA; Paul Hunt, MBA, President, Pricing Solutions, Toronto, ON, Canada

USE OF REAL WORLD DATA

W23: METHODOLOGIES FOR EVALUATING GEOSPATIAL ACCESS IN MEDICATION USE STUDIES  
Jefferson East (Concourse Level)

Discussion Leaders: Rajesh Balkrishnan, PhD, Professor, Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA; Xi Tan, PhD, PharmD, Assistant Professor, Department of Pharmaceutical Systems and Policy, West Virginia University, School of Pharmacy, Morgantown, WV, USA; Joseph Donohoe, PhD, Informatics and Special Projects Lead, Mountain-Pacific Quality Health, Helena, Helena, MT, USA

W24: MISSING DATA IN OBSERVATIONAL STUDIES  
Jefferson West (Concourse Level)

Discussion Leaders: William Hawkes, PhD, Senior Statistical Scientist, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA; Xu (Sherry) Yan, PhD, Team Leader, Therapeutic Statistics Branch I, Division of Biostatistics OSB/CDRH, U.S. Food and Drug Administration, Silver Spring, MD, USA; Zhaohui Su, PhD, Vice President, Biostatistics, Better Outcomes Corporation, Cambridge, MA, USA; Aaron B. Mendelsohn, PhD, MPH, Director, Epidemiology, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA
ISPOR 21st ANNUAL INTERNATIONAL MEETING
May 21-25, 2016 | Washington Hilton | Washington, DC, USA

PROGRAM & SCHEDULE OF EVENTS: WEDNESDAY, MAY 25

CLINICAL OUTCOMES RESEARCH

W25: SURVIVAL CURVES WITH NON-RANDOMIZED DESIGNS: HOW TO ADDRESS POTENTIAL BIAS AND INTERPRET ADJUSTED SURVIVAL CURVES  Lincoln East (Concourse Level)
Discussion Leaders: Abdalla Aly, BPharm, PhD, Scientist, Health Economics and Outcomes Research, Pharmerit International, Bethesda, MD, USA; Eberechukwu Omukwugha, MS, PhD, Associate Professor, Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD, USA; Tony Okoro, PharmD, Senior Manager, Bristol-Myers Squibb, Plainsboro, NJ, USA; Caitlyn T. Solem, PhD, Director, Health Economics and Outcomes Research, Pharmerit International, Bethesda, MD, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

W26: PATIENTS AS PARTNERS IN THE DEVELOPMENT AND INTERPRETATION OF CLINICAL OUTCOME ASSESSMENTS: METHODS, CHALLENGES, AND BENEFITS  Lincoln West (Concourse Level)
Discussion Leaders: Milena Anatchkova, PhD, Research Scientist, Outcomes Research, Evidera, Lexington, RI, USA; Theresa Mullin, PhD, Director, Office of Strategic Programs, U.S. Food and Drug Administration, Silver Spring, MD, USA; Linda S. Deal, MSc, Senior Director & Head of Patient-Centered Outcomes Measurement, Pfizer, Collegeville, PA, USA; Alice Bast, BS, Chief Executive Officer, Beyond Celiac, Ambler, PA, USA

2:45PM-3:00PM  BREAK  Concourse Lobby

3:00PM-4:00PM  WORKSHOPS - SESSION V

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W27: COMMUNICATION AND OUTCOMES: IMPLEMENTING A MULTI-STAKEHOLDER COMMUNIMETRIC SYSTEM IN A BEHAVIORAL HEALTH SETTING  Georgetown (Concourse Level)
Discussion Leaders: Dan Warner, PhD, Executive Director & Founder, Community Data Roundtable, Harrisburg, PA, USA; Larry Nulton, PhD, CEO, Nulton Diagnostic & Treatment Center, Johnstown, PA, USA; Pamela Marple, MBA, HealthChoices Coordinator, Behavioral Health Services of Somerset and Bedford Counties, Somerset, PA, USA; James A. Laughman, LSW, Executive Director, PerformCare, Harrisburg, PA, USA

USE OF REAL WORLD DATA

W28: WE’RE FIVE YEARS IN… HAS ELECTRONIC HEALTH RECORDS (EHR) DATA MET OUR EXPECTATIONS? SUCCESSES AND CHALLENGES WHEN USING INTEGRATED ADMINISTRATIVE CLAIMS AND EHR DATA TO GENERATE ECONOMIC EVIDENCE, MANAGE POPULATION HEALTH, AND EVALUATE COMPARATIVE EFFECTIVENESS  Jefferson East (Concourse Level)
Discussion Leaders: Aylin Altan, PhD, Vice President, HEOR, Optum Labs, Eden Prairie, MN, USA; John Cuddeback, MD, PhD, Vice President, American Medical Group Association, Alexandria, VA, USA; Lindsey R. Sangaralingham, MPH, Senior Health Services Analyst, Mayo Clinic, Rochester, MN, USA; Christopher Hane, PhD, Vice President, OptumLabs, Minneapolis, MN, USA

W29: THE HEALTH ECONOMICS AND OUTCOMES RESEARCH APPLICATIONS AND VALUATION OF DIGITAL HEALTH TECHNOLOGIES AND MACHINE LEARNING  Jefferson West (Concourse Level)
Discussion Leaders: Mei Sheng Duh, MPH, ScD, Managing Principal, Analysis Group, Inc., Boston, MA, USA; Gigi Yuen-Reed, PhD, Senior Research Scientist, IBM Watson Health, Tampa, FL, USA; Sherri Rose, PhD, Assistant Professor of Biostatistics, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA; Steven Pashko, PhD, Principal Offering Manager, IBM Watson Health – Real World Evidence, Wayne, Philadelphia, PA, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH

W30: SECONDARY ANALYSIS OF QUALITATIVE DATA TO INFORM THE DEVELOPMENT OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS  Lincoln East (Concourse Level)
Discussion Leaders: Monica Hadi, PhD, Research Manager, Mapi Group, London, UK; Paul Swinburn, MRes, Research Director, Mapi Group, London, UK; Elizabeth Gibbons, MSc, Senior Research Scientist, Health Services Research Unit, University of Oxford, Oxford, UK

W31: SOME NEW STRATEGIES FOR ELICITING AND MODELING UTILITY VALUES OF MULTI-ATTRIBUTE HEALTH STATES  Lincoln West (Concourse Level)
Discussion Leaders: Nan Luo, PhD, Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Kim Rand-Hendriksen, PhD, CPsychol, Post Doctoral Fellow, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway; Juan Manuel Ramos-Goñi, MSc, Research Scientist, The EuroQol Group Foundation, Rotterdam, The Netherlands